Developing Novel Therapeutic Strategies for Pancreatic Cancer using Targets Identified by Next Generation Sequencing

使用下一代测序确定的靶点开发胰腺癌的新治疗策略

• 批准号: nhmrc : 1036603
• 负责人: Dr David Chang
• 金额: $ 24.91万
• 依托单位: Garvan Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: Early Career Fellowships
• 财政年份: 2012
• 资助国家: 澳大利亚
• 起止时间: 2012-01-01 至 2017-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/developing-novel-therapeutic-generation-sequencing/111024
• 关键词: Developing; Novel; Therapeutic; Strategies; Pancreatic

Dr David Chang is a surgeon scientist who specialises in the treatment of pancreatic cancer. His research focus is on the development and implementation of novel therapeutic strategies for pancreatic cancer. He aims to achieve this by utilising novel biomarkers that have the ability to forecast prognosis and response to treatments. Ultimately, this will lead to the “individualised” treatment for each patient.

大卫张医生是一位外科医生科学家，专门从事胰腺癌的治疗。他的研究重点是胰腺癌新治疗策略的开发和实施。他的目标是通过利用能够预测预后和对治疗反应的新型生物标志物来实现这一目标。最终，这将导致每个患者的“个性化”治疗。